Erythropetin Simulating Agent in Patients with Kidney Disease JCG0019 v2 id 1319
This Joint Trust guideline has been produced to ensure all health care professionals are aware of best practice for administering Erythropoietin ESA to patients with chronic renal failure and anaemia. This includes pre-dialysis patients dialysis patients and transplant patients.
Erythropoietin is a hormone normally produced by the kidneys and production is reduced in deteriorating renal failure. Erythropoietin is used to correct the anaemia.
Clinical GuidelinesThis guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes.
The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document.